Navigation Links
Breakthrough for more efficient drug development
Date:1/18/2011

Developing new drugs is a highly costly and time-consuming process. Of 20 candidates, 19 are normally rejected because they don't work or have unwanted side effects. Now a research team led by Professor Lars Baltzer at Uppsala University has produced a tiny molecular "binder" that has the potential to change this landscape radically.

The study, published today in the prestigious journal Angewandte Chemie, presents the concept of a tiny polypeptide consisting of 42 amino acids to which virtually any target-seeking organic molecule can be bound. In the body it then seeks out the designated sites to be treated. What's unique about the polypeptide is that it dramatically enhances the properties of the little molecule in a simple and very general way.

- This produces superbinders. They bind more strongly and more specifically than other alternatives, says Lars Baltzer, professor of organic chemistry, who believes it will be possible to rapidly develop new drugs much more readily with this new concept.

The whole concept goes against the grain of what is usually done in drug development. Traditionally it's usually a matter of synthesizing drugs from A to Z, with certain requirements needing to be met in order to succeed. Drugs should be low molecular (500 Da), be highly fat soluble, and have no more than ten binding sites in order to pass through the cell membrane. But the majority are ineffective or toxic, and nowadays there are also ways to get larger molecules through cell membranes. Recently therapeutic antibodies have emerged as an alternative. They're large (150,000 Da) and bind to the outside of cells, which they then "block."

The new peptide is 5,000 Da or only 1/30 as large as a typical antibody, which is smaller than was thought possible. But according to Lars Baltzer nature has always signaled that this should work.

- The human growth factor hGH uses 35 amino acids to bind to its receptor, but it turns out that only six of them are critical. The rest can be replaced without significantly changing the function. There's really nothing very special about placing a general peptide on a small molecule, but nobody has done it before, he says.

In this study the peptide was successfully bound to the inflammation marker CRP, which is an indicator of a risk of premature death in heart patients, among other things. Several other studies are underway and are proving to be equally successful.

These findings are of great importance to industry, and several large companies have shown their interest. The spin-out company that was previously formed out of Baltzer's research team is now going to further develop the concept to be able to help the drug industry determine at a considerably earlier stage than today whether a drug candidate is worth pursuing or not.


'/>"/>

Contact: Lars Baltzer
lars.baltzer@biorg.uu.se
46-070-648-2595
Uppsala University
Source:Eurekalert

Related medicine news :

1. Human Dental Technology Leads to Breakthroughs for Pet Dental Health at Sergeants Pet Care Products, Inc.
2. First Breakthrough in Water Heating Technology!
3. New DNA technique leads to a breakthrough in child cancer research
4. Northern Illinois Proton Center on the Verge of Major Medical Breakthrough
5. OvaCue Fertility Monitor Breakthrough Allows Women to See Fertility Color-coded on a Calendar Over Time
6. National Event Addresses Breakthroughs in Crohn's & Colitis Research: National Expert & Researcher Answers Key Questions on Interactive Webcast/Teleconference
7. Breakthroughs in treatment of spine and back conditions
8. buySAFE, Inc. Releases a Breakthrough White Paper that is a Must Read for Every Internet Retailer Interested in Increasing Website Conversion
9. Tampa Bay Vein Treatment and Cosmetic Dermatology Practice Using New Laser Technology Some Say is the Latest Breakthrough
10. Breakthrough for babies born with severe cleft palates after experiments at ISIS
11. Gene-Targeted Cancer Fix Could Be a Breakthrough
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on his ... the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his family ... hospital’s 30th heart transplant recipient. , “He was playing at home, when we got ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving back to ... fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. AlignLife ... children of the world. , In exchange for generous donations, customers will receive a ...
(Date:12/7/2016)... OR (PRWEB) , ... December 07, 2016 , ... Sharon ... Water, Global Climate Change and Your Health on Voice of America, declared on her ... to call attention to the fact that when these bullies attack leaders in corporate ...
(Date:12/7/2016)... ... 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers Delightful Holiday ... Up To 33% Off Botox® and Juvederm® Products Now Through December 31, 2016 , ... Delightful Deals on Botox® and Juvederm® just in time for the holiday party ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, ... medicines company, announced today that it entered into ... RNA-based therapeutics for the treatment of NASH and ... therapeutic delivery platform LUNAR™ and UNA Oligomer chemistry. ... "Given Takeda,s long-standing commitment to and expertise in ...
(Date:12/6/2016)... 2016  Regulus Therapeutics Inc. (NASDAQ: ... and development of innovative medicines targeting microRNAs, today ... R&D day, held in New York ... anti-miR targeting microRNA-27 (miR-27) for the treatment of ... anti-miR targeting microRNA-17 (miR-17) for the treatment of ...
(Date:12/6/2016)... A new study released today by the ... the 340B Drug Pricing Program will continue to expand at ... expected to exceed $23 billion in total purchases at the ... current Medicare Part B drug reimbursement purchases over the next ... on analysis of data on total drug purchases through 340B ...
Breaking Medicine Technology: